Pathological Gambling in Parkinson Disease Is Reduced by Amantadine

被引：142

作者：

Thomas, Astrid ^{[1
,2
]}

Bonanni, Laura ^{[1
,2
]}

Gambi, Francesco ^{[3
]}

Di Iorio, Angelo ^{[4
]}

Onofrj, Marco ^{[1
,2
]}

机构：

[1] Univ G DAnnunzio, Dept Neurol, Chieti, Italy

[2] Gabriele dAnnunzio Univ Fdn, Aging Res Ctr CeSI, Chieti, Italy

[3] Univ G DAnnunzio, Inst Clin Psychiat, Dept Oncol & Neurosci, Chieti, Italy

[4] Univ G DAnnunzio, Dept Med & Aging, Lab Clin Epidemiol, Geriatr Unit, Chieti, Italy

来源：

ANNALS OF NEUROLOGY | 2010年 / 68卷 / 03期

关键词：

DOPAMINE DYSREGULATION SYNDROME; RELIABILITY; PSYCHOSIS; THERAPY; DRUG;

D O I：

10.1002/ana.22029

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

To investigate the possible efficacy of amantadine in the control of pathological gambling (PG) associated with Parkinson disease (PD), 17 PD patients with PG were randomly selected for a double-blind crossover study with amantadine 200mg/day versus placebo and an open follow-up. Assessments included PG-specific scales (Yale-Brown Obsessive-Compulsive Scale for PG, Gambling-Symptom Assessment Scale, South Oaks Gambling Screen) and assessment of expenditures and time spent gambling. Amantadine abolished or reduced PG in all treated patients, as confirmed by scale score and daily expenditure reduction. Amantadine might be useful to treat PG. The effect of amantadine, acting as an antiglutamatergic agent, also opens new insights into the pathogenesis of PG. ANN NEUROL 2010;68:400-404

引用

页码：400 / 404

页数：5

共 25 条

[1]

[Anonymous], J AM MED ASS

[2] A reassessment of risks and benefits of dopamine agonists in Parkinson's disease [J].

Antonini, Angelo ;

Tolosa, Eduardo ;

Mizuno, Yoshikuni ;

Yamamoto, Mitsutoshi ;

Poewe, Werner H. .

LANCET NEUROLOGY, 2009, 8 (10) :929-937

[3] THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].

CUMMINGS, JL ;

MEGA, M ;

GRAY, K ;

ROSENBERGTHOMPSON, S ;

CARUSI, DA ;

GORNBEIN, J .

NEUROLOGY, 1994, 44 (12) :2308-2314

[4] Dopamine dysregulation syndrome in Parkinson's disease [J].

Evans, AH ;

Lees, AJ .

CURRENT OPINION IN NEUROLOGY, 2004, 17 (04) :393-398

[5]

Fahn S., 1987, RECENT DEV PARKINSON, V2

[6] Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease [J].

Fenu, Sandro ;

Wardas, Jadwiga ;

Morelli, Micaela .

BEHAVIOURAL PHARMACOLOGY, 2009, 20 (5-6) :363-379

[7] Non-dopaminergic treatments in development for Parkinson's disease [J].

Fox, Susan H. ;

Brotchie, Jonathan M. ;

Lang, Anthony E. .

LANCET NEUROLOGY, 2008, 7 (10) :927-938

[8] Management of impulse control disorders in Parkinson's disease [J].

Galpern W.R. ;

Stacy M. .

Current Treatment Options in Neurology, 2007, 9 (3) :189-197

[9] ACCURACY OF CLINICAL-DIAGNOSIS OF IDIOPATHIC PARKINSONS-DISEASE - A CLINICOPATHOLOGICAL STUDY OF 100 CASES [J].

HUGHES, AJ ;

DANIEL, SE ;

KILFORD, L ;

LEES, AJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (03) :181-184

[10] The glutamate homeostasis hypothesis of addiction [J].

Kalivas, Peter W. .

NATURE REVIEWS NEUROSCIENCE, 2009, 10 (08) :561-572

← 1 2 3 →